ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2025-05-01
DOI
https://doi.org/10.17615/tde0-ye85
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

Ayman M. Abdelhamed, David A. Six, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace et al.
UNC Libraries
Antibiotic Resistance in Bacteria
article

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

Ayman M. Abdelhamed, David A. Six, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace, Kristine M. Hujer, Andrea M. Hujer, Andrew R Mack, Vance G. Fowler, Steven H. Marshall, Daniel D. Rhoads, Greg Moeck, Robin Patel, David van Duin, Michael R. Jacobs, Robert A Bonomo, Christopher R. Bethel, Caryn E. Good
article en

Abstract

Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.

UNC Libraries
University of North Carolina at Chapel Hill (US)
U.S. Department of Health and Human Services, U.S. Department of Veterans Affairs, Office of Research and Development, Shionogi, Wockhardt, National Institutes of Health, Biomedical Advanced Research and Development Authority, Geriatric Research Education and Clinical Center, National Institute of Allergy and Infectious Diseases, NIH Clinical Center
Openalex Percentile: Top 71%
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.